Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
75.54
-0.21 (-0.28%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today
↗
April 16, 2025
Via
Benzinga
Investors seeking growth at a reasonable cost should explore CORCEPT THERAPEUTICS INC (NASDAQ:CORT).
↗
April 15, 2025
NASDAQ:CORT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Via
Chartmill
3 Biopharmaceutical Stocks Bucking the Sell-Off
April 10, 2025
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.
Via
MarketBeat
Topics
World Trade
Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks
April 10, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
April 08, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
April 07, 2025
From
Corcept Therapeutics Incorporated
Via
Business Wire
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4)
↗
April 06, 2025
Mid-cap stocks surged in the past week, including CORT, COOP, and CRWV. GOOG may rent AI servers from CRWV. PRGS and LOAR reported strong results.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
April 01, 2025
Via
Benzinga
Top stock movements in today's session.
↗
March 31, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings)
↗
March 31, 2025
Via
Benzinga
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
↗
March 31, 2025
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.
Via
Benzinga
Why Is Corcept (CORT) Stock Soaring Today
March 31, 2025
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving...
Via
StockStory
Topics
Artificial Intelligence
Monday's session: top gainers and losers
↗
March 31, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
↗
March 31, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
March 31, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
↗
March 31, 2025
Via
Benzinga
Topics
Stocks
Mr. Cooper Group, Southern States Bancshares, Corcept Therapeutics And Other Big Stocks Moving Higher On Monday
↗
March 31, 2025
Via
Benzinga
Monday's pre-market session: top gainers and losers
↗
March 31, 2025
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Via
Chartmill
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
↗
March 31, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 31, 2025
Via
Benzinga
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
March 31, 2025
From
Corcept Therapeutics Incorporated
Via
Business Wire
3 Reasons to Sell CORT and 1 Stock to Buy Instead
March 26, 2025
Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the...
Via
StockStory
Topics
Stocks
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued.
↗
March 24, 2025
Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive...
Via
Chartmill
3 Growth Stocks in Hot Water
March 19, 2025
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...
Via
StockStory
1 Small-Cap Stock on Our Buy List and 2 to Avoid
March 14, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
March 10, 2025
From
Corcept Therapeutics Incorporated
Via
Business Wire
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
March 04, 2025
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
March 04, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
March 03, 2025
From
Corcept Therapeutics Incorporated
Via
Business Wire
Why Corcept (CORT) Shares Are Sliding Today
February 27, 2025
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.3% in the pre-market session after the company reported weak fourth quarter results: its revenue missed significantly, and its EPS...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today